摘要
目的 :探讨瑞格列奈治疗Ⅱ型糖尿病的疗效。方法 :Ⅱ型糖尿病患者 40例 ,给予瑞格列奈治疗 ,均在每餐前 15min服瑞格列奈 0 .5mg ,加餐时进食前加服 1次 ,误餐者停服 1次。每 2周检测 1次空腹血糖 (FBG)及餐后 2h血糖 (P2hBG) ,血糖控制不理想者将每餐前瑞格列奈剂量加至 1.0～ 1.5mg。观察时间为 12周。比较治疗前后血脂、血糖、胰岛素的变化。结果 :瑞格列奈治疗后FBG、P2hBG、糖化血红蛋白、三酰甘油均显著下降 (P <0 .0 1) ,餐后 2h胰岛素明显升高 (P <0 .0 5 )。结论 :瑞格列奈是治疗Ⅱ型糖尿病的有效降血糖药物 ,不良反应及低血糖发生率低 。
Objective:To analyze the therapeutic effectiveness of repaglinide in the treatment of Type Ⅱ diabetes mellitus. Method:40 patients with Type Ⅱ diabetes mellitus meeting the 1985 WHO diagnosis criteria were treated with repaglinide. Patients were given each 0.5 mg of repaglinide PO 15 min before each meal. A supplementary dose was administered before an additional meal. If a meal was missed, the corresponding dose was omitted. Fasting blood glucose and 2 h postprandial blood glucose were determined fortnightly. The dose of repaglinide was increased to 1.0～1.5 mg before meal if blood glucose had not been well controlled. The observation lasted 12 weeks. Levels of blood lipid, glucose and insulin before and after the treatment were compared. Results:A remarkable fall in the levels of fasting and 2 h postprandial blood glucose, glycosylated hemoglobin and tyiglyceride was demonstrated ( P <0.01) after the treatment. In the meantime, the level of 2 h postprandial insulin rose significantly ( P <0.05). Conclusion:Repaglinide is an effective remedy in the treatment of diabetes mellitus. The incidence of adverse reactions including hypoglycemia is low. It may improve the diabetics' compliance with treatment.
出处
《医药导报》
CAS
2002年第8期485-486,共2页
Herald of Medicine
